Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease.

ABSTRACT:

Objective

Alzheimer's disease (AD) studies are increasingly targeting earlier (pre)clinical populations, in which the expected degree of observable cognitive decline over a certain time interval is reduced as compared to the dementia stage. Consequently, endpoints to capture early cognitive changes require refinement. We aimed to determine the sensitivity to decline of widely applied neuropsychological tests at different clinical stages of AD as outlined in the National Institute on Aging - Alzheimer's Association (NIA-AA) research framework.

Method

Amyloid-positive individuals (as determined by positron emission tomography or cerebrospinal fluid) with longitudinal neuropsychological assessments available were included from four well-defined study cohorts and subsequently cl

SUBMITTER: Jutten RJ 

PROVIDER: S-EPMC8041916 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature